Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.